News & Views
Partnership to Provide Clinical Development Services
Aug 10 2015
ICON plc is to provide recently formed Mereo BioPharma Group Ltd with clinical development services and solutions. Mereo is a new UK company that is focused on acquiring, rapidly developing and commercialising innovative medicines that are targeted at rare and specialist disease areas. The company’s initial portfolio consists of clinical-stage products acquired from Novartis and are targeted at brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease and hypogonadotropic hypogonadism.
Commenting on the partnership, Ciaran Murray, CEO, ICON plc, said: “We are delighted to have been selected as Mereo’s clinical development partner. It is a further endorsement of ICON’s expertise in operating under partnership models which leverage our deep industry expertise, operational excellence and differentiated technology solutions. We look forward to helping Mereo accelerate the development of their pipeline and bring to market drugs that will enhance the quality of patients lives.”
Mereo BioPharma’s CEO, Dr Denise Scots-Knight, commented: “Our partnership with ICON provides us with a dedicated and experienced global team that is already working closely with Mereo. The relationship is designed not only to help us conduct global clinical studies as we develop our product portfolio, but also to leverage ICON’s broader consulting expertise. We look forward to a fruitful alliance, progressing our pipeline in the clinic and ultimately delivering new valuable medicines to patients.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan